Navigation Links
The Merz Pharma Group Appoints William D. Humphries As New North American Chief Executive Officer
Date:3/14/2012

GREENSBORO, N.C., March 14, 2012 /PRNewswire/ -- The Merz Pharma Group today announced that William (Bill) D. Humphries has been appointed CEO of the US holding company, Merz Inc., effective March 15, 2012.  In his new role, Humphries will assume overall responsibility for the Medical Dermatology global business unit and will oversee strategic direction and collaboration among three North American companies: Merz Pharmaceuticals, LLC, Merz Aesthetics, Inc. and Merz Pharma Canada, Ltd. 

"Few people can match Bill's extensive knowledge across the pharmaceutical and aesthetic medicine categories.  His knowledge, combined with his unparalleled experience as an innovative driver of organic and acquired expansion, brings a new era of leadership to the Merz companies," said Dr. Martin Zugel, CEO Merz Pharmaceuticals GmbH. "We are confident that Bill will lead our companies into a period of accelerated growth in the North American market."

Humphries' appointment completes the latest senior executive talent additions to Merz, including the hiring of Hans Regenauer, Head of Global Business Unit OTC/OTX & Emerging Markets; and Stefan Brinkmann, Head of Global Business Unit Ethical Pharma and Regional Head Western Europe.

Prior to joining Merz, Humphries served as the President of Stiefel, a leader in global dermatology and skin health. During his tenure at Stiefel (now a subsidiary of GlaxoSmithKline), Humphries spearheaded two major acquisitions, and led the global integration of Stiefel into GlaxoSmithKline.  Under his leadership, Stiefel experienced compounded revenue growth of 34% annually over five years, reaching a total of $847 million in 2009. Previously Humphries held multiple senior executive roles within Allergan, Inc., concluding as Vice President of the U.S. Skincare business.

Humphries holds a Bachelor of Arts from Bucknell University in Lewisburg, Pa., and an MBA from Pepperdine University in Malibu, Calif. He also holds seats on the boards of The American Skin Association and Clearside Biomedical. He will operate primarily from the Merz Pharmaceuticals, LLC offices in Greensboro, N.C.

About The Merz Pharma Group

Globally, the companies of the Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses and thereby assume a leading role in the field of Alzheimer research.  With Memantine, Merz has developed the world`s first glutamateric drug for the treatment of moderate to severe stages of Alzheimer dementia. Memantine is the second most frequently prescribed antidementive medication in the world. Another important area of competency of Merz is Clinical Dermatology and Aesthetic Medicine. Merz is also active in the Health sector outside of the pharmacy. In the field of consumer products, with its established brands of tetesept® and Merz Spezial®, Merz Consumer Care is a leading provider of products for self-medication, nutritional supplements and skin care in the German-speaking area. The Merz Pharma Group is a privately owned company, founded 1908 in Frankfurt, Germany.

About Merz Pharmaceuticals, LLC

Merz Pharmaceuticals, LLC is a wholly-owned subsidiary of Merz Inc. and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Physiatry, Dermatology, and Podiatry.

About Merz Aesthetics

Merz Aesthetics, Inc. is a wholly-owned subsidiary of Merz Inc. and a member of the Aesthetics Global Business Unit of Merz Pharma which has affiliates in 17 countries and cooperates with more than 30 distributors worldwide.

About Merz Pharma Canada Ltd.

Merz Pharma Canada Ltd., a wholly owned subsidiary of the Merz Group of Companies, was established in 2009 to expand Merz franchises in the Canadian Marketplace.


'/>"/>
SOURCE Merz Pharma Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):